electroCore, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -21.1% over 5Y.
today you would have $656.05▼ -34.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $4.49 | $16.21 | $5.95 | $3.86 | $8.74 | $23.40 | $23.85 | $93.90 | |
| P/S | 6.1x | 1.1x | 4.6x | 2.2x | 2.1x | 7.6x | 21.6x | 19.9x | 185.6x |
| P/B | 2.8x | — | 15.5x | 4.8x | 1.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |
| OKYOOKYO Pharma Ltd | $1.67 | — | 7.1x | — | -263.78% | $87.64M |
| ACETAdicet Bio, Inc. | $9.15 | — | 0.8x | — | -78.08% | $85.61M |
| GUTSFractyl Health Inc | $0.55 |
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Company description provided by Yahoo Finance.
| 1.1x |
| 3.3x |
| 2.0x |
| 2.8x |
| EPS | -$1.65 | -$1.59 | -$3.42 | -$4.69 | -$4.36 | -$9.00 | -$23.10 | -$17.85 |
| Profit margin | -286.90% | -43.60% | -47.20% | -117.49% | -257.94% | -315.87% | -672.55% | -1888.81% | -5621.66% |
| ROE | -129.71% | — | -157.56% | -253.08% | -129.71% | -46.98% | -102.18% | -186.09% | -85.16% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $88.03M |
| HYPRHyperfine, Inc. | $0.83 | — | 2.4x | — | -96.97% | $88.36M |
| ATRAAtara Biotherapeutics, Inc. | $8.81 | — | — | — | — | $88.43M |